Adenoid Cystic Carcinoma clinical trials at UCSF

• Phase 2 Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic ACC

  open to eligible people ages 18 years and up

  This is a Phase 2, multicenter, open-label, single-arm study of rivoceranib to evaluate its efficacy and safety in adult subjects with metastatic ACC of all anatomic sites of origin.

  San Francisco, California and other locations

Last updated: July 26, 2020